Why Lexaria’s Patents Represent a Big Opportunity — CFN Media

SEATTLE, April 18, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Biosciences Corp.’s (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP) diligent focus on building up their patent portfolio covering the DehydraTECH™ technology. By addressing key issues with bioavailability, the company’s DehydraTECH™ platform can be used with both patented and generic API substances. The company’s portfolio of more than 35 patent applications across 40 countries has already opened the door to new licensing agreements — and it’s just getting started.

The initial “green rush” may have been to expand production capacity in legal states and countries, but the cannabis industry’s next biggest opportunity is in patents. By building a patent portfolio early on, companies can obtain key intellectual property rights that will convey a broad market advantage as the industry matures. Investors benefit from both a legal monopoly and the opportunity to generate royalty income from licensing.

Importance of Patents

The cannabis industry is a blue sky opportunity for innovative companies looking to build a patent portfolio covering plant strains, breeding methods, extraction techniques, growing technologies, proprietary software, and novel therapeutics. According to Google Patents, there are around 137,734 mentions of “marijuana” or “cannabis” in patents registered with the U.S. Patent and Trademark Office, and that figure is rapidly growing in the new “gold rush”.

Companies that start building a patent portfolio at these early stages may obtain key intellectual property rights that will convey a broad market advantage. In addition, these companies will have the ability to exclude competitors from the marketplace or create ongoing royalty revenue by licensing the patent to third parties. These patents are also a great investment with a 20-year amortized cost of just $1,750 per year, according to Marijuana Venture.

Investors may want to take a closer look at companies within the cannabis industry that are aggressively building out their intellectual property portfolios. These companies could represent lucrative opportunities as the industry matures, particularly if their patents address important problems within the industry. For example, cannabinoid bioavailability, efficient extraction, pesticide-free growing, and other issues could be lucrative areas of focus.

Building a Patent Portfolio

Lexaria Biosciences has recognized the value of building a patent portfolio early on and decided to focus on innovative delivery systems. Over the past several years, the company has built up a portfolio of more than 35 patent applications across 40 countries around the world. Management plans to continue making new patent application filings during 2018 and anticipates more rewards over the coming year.

On April 11, the company announced that it received a notice of allowance provided claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology. The news follows its March 22 announcement of the notice of allowance for the composition of matter claim for the technology. These two notices of allowance are expected to become its third and fourth granted patents in the United States.

The company’s six current patent families covering DehydraTECH™ include:

  1. “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”
  2. “Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents”
  3. “Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents”
  4. “Microwave Processing Methods for Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents”
  5. “Food and Beverage Compositions Comprising PDE5 Inhibitors”
  6. “Transdermal Delivery of Lipophilic Active Agents”

These patents provide a key barrier to entry when it comes to competing technologies that attempt to use the same techniques to improve bioavailability. At the same time, the patents open the door to licensing opportunities to generate royalty income. Several companies have already entered into licensing agreements to use the innovative technology in their own products to improve the taste and bioavailability of cannabinoids.

Looking Ahead

Lexaria Biosciences Corp. (OTCQX:LXRP) (CSE:LXX) represents a compelling opportunity in the burgeoning cannabis industry. By building an intellectual property portfolio early on, the company hopes to create significant barriers to entry for its DehydraTECH™ platform as well as open the door to royalty revenue from licensing agreements. Investors may want to keep a close eye on the stock given these developments.

For more information, visit the company’s website or download their investor presentation.

Please follow the link to read the full article: http://www.cannabisfn.com/lexarias-patents-represent-big-opportunity/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com


CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

Frank Lane